Shiells H et al., 2020: In a 52-week randomised phase 3 trial, insomnia was one of the adverse events whose incidence rose with the higher dose of the methylene-blue-derived drug (oral, 8 mg/day vs 200 mg/day) – a documented dose-related sleep effect.
TEAEs that showed an increase in incidence with hydromethylthionine 200 mg/day relative to 8 mg/day include anemia, diarrhea, dysuria, nausea, pollakiuria, insomnia, and vomiting.
Shiells H et al., 2020: In a 52-week randomised phase 3 trial, insomnia was one of the adverse events whose incidence rose with the higher dose of the methylene-blue-derived drug (oral, 8 mg/day vs 200 mg/day) – a documented dose-related sleep effect. Journal of Alzheimer's Disease 2020;75(2):501-519. Type: randomised, double-blind phase 3 trial. N=220 (110 at 8 mg/day, 108 at 200 mg/day per the trial report). Country: UK/international sites. Drug: hydromethylthionine (reduced form of methylene blue), oral 8 mg/day vs 200 mg/day for 52 weeks. Funder: TauRx Therapeutics (authors are TauRx staff). Declared conflicts: authors affiliated with TauRx Therapeutics Ltd. Product maker: TauRx. Comparator: low-dose active (8 mg/day) used as control. Also filed as MTH-064 (claims C9, F7). Study type: randomized trial.
